Biotech entity
All 1 tracked stories fall under one category: gene-therapy. Bank of America is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Steve Pakola appears in 1 tracked Biotech story from July 6, 2026.
Last mentioned: Jul 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: gene-therapy. Bank of America is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Steve Pakola appears in 1 tracked Biotech story from July 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Steve Pakola. Shared-story counts are live from our verified record — not editorial picks.
REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Source: Zolmax · Markets Daily
Steve Pakola is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
